News
A Second Career As A Biotech CEO
It’s not surprising that Steven Yatomi-Clarke started his second career at a company named Prescient Therapeutics. In his first career as an investment banker, like…
News
Blood Cancer Therapy Now Available In Australia
The nation’s youngest cancer patients have been given new hope, with a cutting-edge treatment being brought to Australia.
News
Prescient Therapeutics
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The last earnings update…
News
Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100
On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple…
News
Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers
Highlights: Innovative ‘basket’ study design will assess drug in multiple cancers Precision medicine approach offers a potentially faster development route International cancer expert Prof Miles…
News
Prescient Therapeutics’ drug candidates addressing the mutations causing cancer
Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company’s mainstream…
